SenesTech, Inc. (SNES)
NASDAQ · Chemicals · Agricultural Chemicals
- Price
- $0.78
- Day
- -0.20%
- Market cap
- $4.23M
Close 2026-09-23.
The company
Overview We have developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Our current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse. As far back as we can trace, rodents have been foes to mankind. Today, they remain one of the most resilient and economically destructive vertebrate pests on the planet. Rodents threaten human and animal health, food security, and infrastructure worldwide, and humanity has spent centuries attempting to mitigate the problems associated with their proliferation. Rodents pose threats to human and animal health, food security and infrastructure around the world, and humanity has spent centuries trying to mitigate the problems associated with these pests. Rodents are known to be reservoir hosts for at least 60 zoonotic diseases and the potential transmission of these diseases creates a global risk to public health and safety, as well as agriculture, affecting crops, livestock, stored grain, and farm workers. Diseases such as leptospirosis and salmonellosis directly impact reproductive efficiency in livestock, contaminate feed supplies, and increase liability exposure for agricultural operators.
From Item 1: Overview.
By product & service
- Product Sales — 100%
- Grant Revenue — 0%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- SABBY MANAGEMENT, LLC — $211.22K
- RENAISSANCE TECHNOLOGIES LLC — $123.1K
- CITADEL ADVISORS LLC — $69.54K
- GEODE CAPITAL MANAGEMENT, LLC — $54.7K
- VANGUARD CAPITAL MANAGEMENT LLC — $51.8K
- VANGUARD FIDUCIARY TRUST CO — $39.62K
- ESSEX INVESTMENT MANAGEMENT CO LLC — $39.04K
- NORTHERN TRUST CORP — $26.2K
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Edell Michael (Chief Executive Officer) bought 1,000 shares at $0.84 on 2026-09-14
- Edell Michael (Chief Executive Officer) bought 1,000 shares at $0.89 on 2026-09-09
- Edell Michael (Chief Executive Officer) bought 1,000 shares at $0.85 on 2026-09-09
- Edell Michael (Chief Executive Officer) bought 1,000 shares at $1.21 on 2026-08-14
- GLENBROOK CAPITAL MANAGEMENT (TenPercentOwner) bought 6,490 shares at $1.30 on 2026-08-07
- GLENBROOK CAPITAL MANAGEMENT (TenPercentOwner) bought 15,000 shares at $1.30 on 2026-08-06
Recent filings
- 4 — 2026-09-15
- 4 — 2026-09-10
- S-8 — 2026-08-20
- 4 — 2026-08-17
- 4 — 2026-08-10
- 10-Q — 2026-08-06
- 8-K — 2026-08-05
- 8-K — 2026-08-03
- SCHEDULE 13D — 2026-07-23
- 4 — 2026-07-22